Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00233571
NCT00233571
Completed
Phase 3

A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)

Abbott0 sites796 target enrollmentJune 2000
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRheumatoid Arthritis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Abbott
Enrollment
796
Primary Endpoint
Clinical response indicators
Status
Completed
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in patients with rheumatoid arthritis

Registry
clinicaltrials.gov
Start Date
June 2000
End Date
June 2006
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Abbott
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Completion of a previous D2E7 study
  • •Subject is in good health (Investigator discretion) with a recent stable medical history

Exclusion Criteria

  • •Former enrollment in this trial (DE018)
  • •Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • •Female subject who is pregnant or breast feeding or considering becoming pregnant.

Outcomes

Primary Outcomes

Clinical response indicators

Time Frame: 5 years

Secondary Outcomes

  • Safety parameters(5 years)

Similar Trials

Completed
Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisPsoriasis
NCT00195676Abbott1,469
Completed
Phase 3
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitisUveitis
NCT01148225AbbVie424
Completed
Phase 3
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic ArthritisPsoriatic Arthritis
NCT00195689Abbott400
Completed
Phase 3
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)Generalized Pustular Psoriasis (GPP)AdalimumabJapanese
NCT02533375AbbVie10
Enrolling By Invitation
Phase 3
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusSystemic Lupus Erythematosus
NCT04976322UCB Biopharma SRL760